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Background
On Friday 2 January 2004, two separate
groups of diners contacted the
Communicable Diseases Section (CDS)
of the Department of Human Services
(hereafter referred to as the
department) to advise that members of
each group had developed diarrhoea
and vomiting after dining at a pizza and
pasta restaurant in inner Melbourne in
late December. Prior to contact with
the department, one person from each
group had been diagnosed with
salmonellosis that was later typed as
Salmonella Typhimurium phage type 9
(STM 9). Discussion with the local
council (hereafter referred to as the
council) and a review of recent
Salmonella notifications identified two
further groups of diners with cases who
had eaten at the same restaurant. STM
9 had been previously associated with
four outbreaks in Victoria between Jan
2000 and Dec 2003 and there were
618 cases of STM 9 notified to the
department during this period,
including the initial cases associated
with this outbreak (Department of
Human Services, unpublished data).
Environmental and epidemiological
investigations were conducted to
identify possible sources and
implement control measures to prevent
the development of further cases.
Methods
Environmental investigation 
The department advised environmental
health officers at the council of a
possible outbreak and requested that
they conduct a site visit and supervise
a clean up of the premises.  At the site
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visits the council reviewed the
restaurant food preparation and
cleanup processes and collected food
samples. Food samples collected were
forwarded to the Microbiological
Diagnostic Unit (MDU), at the
University of Melbourne, to test for
enteric bacterial organisms. 
Epidemiological investigation
A case series investigation was carried
out to obtain descriptive data on the
exposure and illness histories of the
cases.  Active case finding was
initiated by contacting all groups on the
restaurant’s booking lists between 17
and 31 December. As the business
relies predominantly on “walk-in”
custom (customers without bookings)
these lists were of limited value.
Further case finding was therefore
carried out by interviewing persons
notified to the department with
salmonellosis that resided in the
surrounding suburbs to the premises
and those persons notified with STM 9
between December 2003 and January
2004.  Cases were also identified by
contacting patrons who ate at the
restaurant with known cases and those
who self-reported their illness to the
department or the council. 
Ill persons identified in the case series
investigation were classified as
probable or confirmed cases. A
probable case was defined as a person
who ate food from the premises
between 15 December 2003 and 10
January 2004 and who subsequently
experienced gastrointestinal symptoms
of diarrhoea and/or vomiting with
onset within six days after
consumption. A person who met the
definition of a probable case and
submitted a faecal specimen from
which STM 9 was isolated was defined
as a confirmed case. 
Interviews were conducted using a
structured food and illness history
questionnaire that included the
standard restaurant menu used
throughout the outbreak period.
Patrons of the premises who had dined
with an ill case but had not been unwell
themselves were also interviewed for
the purposes of active case finding and
hypothesis generation. Faecal
specimens were requested from all ill
persons and were forwarded for testing
of bacterial enteric organisms at the
MDU.
The proportion of identified ill cases
that had eaten each menu item was
calculated.  This was also calculated for
specific ingredients that tested positive
for STM 9. Data from the interviews
were entered into an Access 2000©
database and analysed using Stata
7.0©. 
Results
Environmental results
The council conducted site visits on 2
and 9 January 2004 with a clean up
carried out by the proprietors on 2
January 2004. As early case interviews
nominated having eaten pizza at the
premises, the food sampling on 2 and 
9 January focussed on pizza toppings.
On 13 January, following identification
of Salmonella in food samples collected
after the initial clean up, a third site
visit was conducted by the council as
well as CDS and the Food Safety Unit
of the department to further review the
food preparation procedures and to
obtain additional food samples
(including pizza toppings from the pizza
wells, salad and salad dressings, frozen
chicken pieces and chicken schnitzel)
for microbiological testing. 
Twenty food samples were collected
between 2 January 2004 and 13
January 2004.  Of these, STM 9 was
detected in samples of ham, salami,
cooked chicken pieces, and marinara
mix collected on 2 January 2004 from
pizza wells in the pizza preparation
area. Further samples of marinara mix
and cooked chicken pieces collected
on 9 January 2004 were also positive
for STM 9. When the environmental
sample results from specimens
collected on 9 January became
available, the council supervised a
second clean up of the premises on 
13 January in accordance with the
Guidelines for the Investigation of
Gastrointestinal Illness.1
Food handling practices noted during
the site visits highlighted the risks of
cross contamination from raw foods to
cooked products. These included the
preparation and handling of raw
chicken in the pizza preparation area
(including cooking chicken in the pizza
oven where chicken is placed onto
pizza trays, passed along the conveyor,
turned by hand and re-run along the
conveyor then scraped into colanders
to drain), the practice of topping up
pizza ingredient containers on an
ongoing basis with leftover ingredients,
allowing potential pathogens in the
older ingredients to be passed onto
fresher ingredients each time. The food
safety program for the premises did not
address these processes and food
safety program records were not
available on the premises when
requested at the first site visit. Other
issues identified during the site visits
included inadequate hand washing
facilities, inadequate cleaning and
maintenance of the food preparation
areas, and inadequate staff training in
food safety.
On 13 January, the premises closed
voluntarily to conduct the second clean
up and review food-handling practices.
When the restaurant re-opened on 16
January, the council, in conjunction with
the Food Safety Unit, commenced a
monitoring program including sampling
of foods prepared at the premises.
Salmonella was not detected in any
cooked or ready to eat foods from the
premises.
Epidemiological analysis
The CDS conducted 270 interviews,
identifying 90 ill persons: 41 (46 per
cent) confirmed cases and 49 (54 per
cent) probable cases (Figure 1). Two
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persons notified with STM 9 were
believed to have eaten at the restaurant
(based on information from friends or
family), but could not be interviewed to
confirm this information and could
therefore not be counted as cases in
this outbreak. The investigation also
identified two secondary cases in
children (household contacts of
probable or confirmed cases). No food
handlers at the premises reported
having been ill.
Of the 90 ill cases, the median age was
21 years (range: 21 months–68 years).
The sex of the ill cases was distributed
almost equally (male to female
ratio1:1.1). The onset of illness was
from 16 December 2003 to 11 January
2004 and the median incubation period
was two days (range: 0-6 days). Seven
(8 per cent) cases were admitted to
hospital, including two children aged 9
and 15. No deaths occurred among the
probable or confirmed cases. 
Analysis of the food histories of the ill
cases indicated 63 (70 per cent) people
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Figure 1: Epidemic curve, by date of onset, Salmonella Typhimurium
phage type 9 outbreak, Melbourne
had eaten pizza (of any type) at the
restaurant. Forty (44 per cent) of the ill
cases had eaten a pasta or risotto dish.
Some risotto or pasta dishes contained
ham, salami, cooked chicken pieces, or
marinara mix; ingredients stored in the
pizza wells where samples taken
subsequently detected STM 9.
Discussion
The environmental findings, the
isolation of STM 9 from both faecal and
food samples, and the epidemiological
results combine to show this outbreak
was caused by the consumption of
contaminated food from the restaurant
premises between December 2003 and
January 2004. 
STM 9 was isolated from pizza toppings
collected on 2 and 9 January 2004. The
range of food found to contain
Salmonella and the food history
information collected from the cases
suggested that the food handling
problems identified during the site visits
lead to cross contamination of food
items in the pizza preparation kitchen
at the restaurant rather than implicating
one product in particular. 
STM 9 is a common Salmonella serovar
and had been isolated from 10 samples
of chicken meat in Australia in 20012
and from six samples of chicken meat
in 20023. In this outbreak, although the
exact origin of the Salmonella could not
be definitively traced, it seems likely
that the organism was introduced
through the raw chicken and that cross
contamination occurred in the pizza
preparation area where the chicken
was cooked. The practice of cooking
chicken in the pizza oven, and the
handling of raw chicken in the pizza
preparation area, was identified as a
serious risk for cross-contamination.
The potential risk with this process is
that the chicken product may be
undercooked or that cross
contamination could occur and
previously cooked product be
contaminated by dirty surfaces, utensils
or hands. Food safety plans, when used
correctly, should identify possible
cross-contamination risks and outline
the steps the premises are using to
manage that risk. Findings from the
outbreak investigation did lead to a
change in the food preparation
processes at the premises and a review
of the premises’ food safety plan. The
restaurant now cooks chicken pieces to
be used for making pizzas in a separate
preparation kitchen, away from the
pizza preparation area. 
This outbreak demonstrates the
ongoing need for food premises to
ensure their food safety programs
adequately reflect the risk of their
business and that appropriate control
steps are both documented and
followed. 
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Introduction
The willingness of parents to enrol their
healthy children in studies of vaccines,
and other pharmacologic products, is
arguably one of the most important
contributors to the availability of safe
and effective vaccines and medicines
for children. Their participation is
remarkable given that the majority of
these studies are for products still in
development, with safety and efficacy
not yet proven, and with no certainty of
direct benefit to their child. The reasons
why they participate commonly include
altruism, a sense of duty to others, the
chance for personal medical benefits
including access to the new drug or
vaccine and personalised care and
trust in the health care provider, the
institution and sponsor.1-3
Here we review the paediatric vaccine
trials conducted in Melbourne by the
Vaccine & Immunisation Research
Group (VIRG) since 1991 – with a focus
on recruitment. The studies were
predominantly phase II – III clinical trials
of new monovalent or combination
vaccines either as single site or multi-
centric, often international, studies.  
Recruitment and
implementation
VIRG was founded in 1991 and now
operates under the jurisdiction of the
Murdoch Childrens Research Institute
(MCRI) in collaboration with Royal
Children’s Hospital (RCH) and the
University of Melbourne. It is located in
the University’s School of Population
Health. The team is comprised of public
health physicians, epidemiologists,
nurse immunisers, phlebotomists,
doctors and research assistants. 
Studies are conducted according to the
National Health and Medical Research
Council (NHMRC) research guidelines,4
and the International Conference on
Harmonisation – Good Clinical Practice
Guidelines (ICH-GCPG).5 Ethics
approvals are obtained from the RCH
Ethics in Human Research Committee.
The Australian Therapeutic Goods
Administration (TGA) approves the
majority of studies through the Clinical
Trial Notification (CTN) scheme.
Participants are predominantly
recruited with the assistance of
maternal and child health nurses
(MCHNs) at community health centres
and local government immunisation
clinics and registers. Study information
has also been disseminated through
childcare centres and schools (both
primary and secondary). Commercial
advertising for studies has, to date, only
been conducted once.
In contrast to the predominant method
for conducting clinical trials (ie. clinic or
hospital based), all VIRG vaccine trials
are community based. Mobile teams of
doctors, nurse immunisers, research
assistants and phlebotomists,
equipped with portable refrigerators
and emergency kits, perform all study
procedures in participants’ homes at a
time ideally suited to their families. An
initial screening visit of approximately
one hour is conducted prior to
enrolment in which eligibility is
determined and the study is discussed
in detail, including a step-by-step
perusal of the plain language
statements. These visits generally take
approximately one hour to complete.
Families are then given several days to
consider their participation and to
discuss the study with significant
others (for example, their general
practitioner, MCHN and/or other family
members). If they agree, formal
enrolment and informed consent takes
place at the first study visit. Written
informed consent is also obtained from
participants aged 10 years and over.
Study subjects and their families are
not paid for their participation, however
on occasions offers of free, off-study,
NHMRC recommended childhood
vaccines have been made (for example,
varicella vaccine). These offers are
included in the plain language and
consent statements. Of the 12 most
recent studies, this has occurred three
times. Most studies involve
concomitant administration of
Australian Standard Vaccination
Schedule (ASVS) recommended
vaccines.
Recruitment statistics
To date, over 7,500 Melbourne infants,
children and adolescents have
participated in one or more of 25
Phase II – IV vaccine trials.
Participants’ ages have ranged from
newborns to 15 years at the time of
enrolment and the duration of study
participation has ranged from 
30 days–18 months. Recruitment
tracking data were available for 12 of
these studies.
For these 12 studies, a total of 3,981
individuals were screened and 2,229
children (56 per cent) were
subsequently enrolled. It is not known
how many individuals were provided
with information about each of the
studies. Of those screened
approximately 37 per cent were
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referred by MCHNs, 19 per cent via
letters sent from local government
immunisation registers and 11 per cent
from child care centres and schools.
Word of mouth accounted for two per
cent of individuals screened.
Of those screened who were not
enrolled (n = 1,713), 579 (33.8 per
cent) were ineligible according to the
study protocol, 557 (32.5 per cent) had
specific objections to the particular
study (generally too many blood tests
or needles) and for 577 (33.6 per cent)
the reason for non-participation was
either not provided or other reasons
were given (for example, family too
busy, uncomfortable with the nature of
the research). The median proportion
of those screened and subsequently
enrolled per study was 56 percent
(range: 24–73 per cent). 
The median number of study visits per
protocol was four (range: 2–6),
including a median of three vaccination
visits (range: 1–5) and two visits in
which blood samples were obtained
(range: 2–4). The median recruitment
period was 21 weeks (range: 11–38),
with an average of 21 (range: 13–41)
screening visits and 12 (range: 8–17)
recruitment visits conducted per week. 
With the exception of one study in
adolescents that involved five study
visits, the highest recruitment rates (73
and 71 per cent) were obtained for the
studies with the least number of study
visits (two per study).  One of these
studies involved the offer of an off-
study vaccine (varicella). The study with
the lowest recruitment rate consisted
of four study visits over a period of 30
months, with vaccines given on two
visits and blood tests taken at all. An
off study vaccine was offered (varicella
or pneumococcal conjugate vaccine).
This study was abandoned early due to
failure to recruit (discussed below). The
study with the most number of visits
and procedures, an infant study with
six visits over 14 months during which
time they received vaccines five times
(3 separate injections per visit) and had
blood taken four times, had a
recruitment rate of 63 per cent. 
Influences on recruitment
The reasons for why one study recruits
particularly well and another fails are
not well understood and a subject
requiring more systematic review. A
diverse number of factors is likely to
apply and will vary across geographical
and socio-economic boundaries,
including pragmatic reasons such as
the time of year the study gets
underway. Langley et al found that the
most common reasons parents cite for
choosing not to enrol their child was
concern about painful procedures such
as the blood tests and extra
immunisations,1 and our data appear to
support this finding.
Infants in Melbourne are generally
recruited to the studies largely as a
result of the support received for the
studies from MCHNs throughout
Melbourne, the relationship between
new parents and their MCHN, the
convenience of having their child
immunised at home and the type of
vaccine under study. A parent’s
relationship with their primary health
care provider is critical to the decision
to immunise,6-8 and an important
influence on reducing concern about
exposing their child to new or
investigational products.2 Home-based
immunisation is recognised as an
effective mechanism for improving
immunisation acceptability and
coverage.9 This aspect of our studies
reduces the inconvenience associated
with attending a research facility and
the need for additional health care
provider visits for routine
immunisations.
Older children have historically been
more difficult to recruit and this may
reflect the nature of busy family lives
(particularly if both parents are working)
and less contact with maternal and
child health care services. The
recruitment for these studies is often
reliant on childcare centres and
schools, and hence individual contact
at the point information about the study
is first received may be lacking. Studies
in older children and adolescents are
also logistically more complex and
resource intensive due to the need to
coordinate visits around family work
and school hours.
Studies that include vaccines not
publicly funded such as inactivated
polio vaccine (IPV), pneumococcal and
meningococcal conjugates (as a
primary course) and varicella vaccines
within the study protocol (for example,
studies examining concomitant
vaccination) are attractive to parents,
possibly due to the additional personal
medical benefit their child receives at
no financial cost. This is however not
always the case, with one study that
included influenza and varicella
vaccines proving difficult and requiring
an extended recruitment period.
Similarly slow were studies of vaccines
for diseases that did not have a high
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public profile (for example, hepatitis A). 
Specific challenges to recruitment
include anomalies between the
Australian Childhood Immunisation
Register (ACIR) and the Family
Assistance Act, the impact of state and
federal privacy legislation and concerns
about the offers of off-study vaccines
being perceived as inducements.
Children who do not receive the
NHMRC recommended vaccines
according to the Australian Standard
Vaccination Schedule are considered
unimmunised and therefore ineligible
for immunisation incentive payments.
There is no facility within the ACIR to
record children as participants of
vaccine trials. As such, parents must
choose to either be exempted from the
requirements as a conscientious
objector or forgo their benefits, or give
their child another dose of a
recommended, licensed vaccine. This
is despite more being known about the
immunological status of a child in a
study than is known about other
children in the community. This effect
was a major contributor to the
recruitment failure and subsequent
abandonment of one toddler study.
Changes to the privacy legislation now
limit the avenues through which
information about studies can be
disseminated and potential participants
accessed.10 This is now a significant
issue for the recruitment of older
children and adolescents who do not
attend community health centres. A
partial solution to this problem has
been the establishment of an in-house
register of families (identified during
previous recruitment activities) who
have provided written consent to be
contacted when future studies arise.
The database now contains over 1,100
children from approximately 550
families and is growing. Despite this,
innovative recruitment strategies are
required  given that large numbers of
individuals need to receive information
to achieve a relatively small sample
size. In one study, over 15,000 letters
were distributed to eventually recruit
150 participants.
The perception of off study vaccines
constituting an inducement is complex,
and beyond the scope of this paper.
Surprisingly, despite much debate in
the literature,3 11-13 there is little
empirical evidence that such offers do
influence the voluntariness of consent
and/or alter an individual’s perception
of the risks of participation. In the
context of our studies, they are
considered an important additional
health benefit and acknowledgement of
a child’s and his/her family’s
significant contribution to research. 
The future
With over 200 vaccines currently in
development around the world,14 the
willingness of Australian children and
their families to participate in pre-
licensure trials needs to be fostered
and barriers to participation reduced.
The current focus on the development
of adolescent vaccines translates to a
requirement for innovative recruitment,
implementation and retention
strategies, particularly given many
target socially sensitive diseases such
as sexually transmitted and blood-
borne infections. An increasing
regulatory environment, the ever-
growing costs of conducting vaccine
research and the limited non-industry
sources of funding are emerging
threats to the viability of this work in
Australia that must be addressed.
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DrTaylor worked for the department as
a medical officer for 26 years. On 18
March 2004, aged 75 years, she
passed away after a long battle with
cancer. During the course of her career
she worked in a variety of settings. Her
work was tireless, constant, and
focused on achieving the best
outcomes for clients and the
department. Her high standards did not
allow for half measures and she
remained on the emergency medical
on-call roster for communicable
diseases well into her early seventies.  
Earlier in her departmental career she
worked with children at Allambie,
providing medical care and referral for
children who were wards of the State.
This work continued during her time at
Schools Medical Service and Refugee
Screening Program. Her move into the
Department of Human Services’
Communicable Diseases Section saw
the continuation of excellent service
delivery to clients notified to the
department with infectious diseases.  
Her meticulous case histories, record
keeping and data collection have
facilitated public health research,
directed public health initiatives, policy
decisions and supported the
surveillance and control of infectious
diseases specifically meningococcal
disease, Q fever and other zoonotic
diseases.
She was also involved in the
assessment and investigation of
medical practices reported to the
Medical Practitioners Board. Her
forthright honesty in these matters was
directed at improving patient care and
protecting the public. Of particular note
is DrTaylor’s achievement in
developing the Q fever vaccination
program. The illness can have serious
health, economic and social costs for
both the workers and their employer.
DrTaylor’s interest in this disease
resulted in a Q fever vaccination and
doctor training program more than ten
years before a national initiative was
introduced. The program was a cost
effective, comprehensive public health
action which provided protection for at
risk workers, facilitated improved
occupational health and safety
standards, decreased disease
incidence, and facilitated improved
outcomes for clients with Q-Fever
through the provision of information,
support, counselling and opportunities
for referral to specialists. DrTaylor is
recognized nationally as an expert in
the field of Q fever vaccination.
Throughout her career DrTaylor
demonstrated professional integrity,
responsibility, tenacity, honesty and
strength. She has shaped and
influenced public health, acted as a
role model, and been an integral part of
the Communicable Diseases Section.
She will be sadly missed by us and her
colleagues across Victoria.
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A new vaccine for genital
herpes in clinical trials
Herpes simplex viruses (HSV) usually
infect mucocutaneous surfaces and are
among the most common infectious
agents of humans. Infection is
characterised by localised lesions,
latency and a tendency to reactivate.1
HSV type 1 (HSV-1) usually involves the
oro-labial region and is acquired early in
life. HSV type 2 (HSV-2) is usually
sexually transmitted and predominantly
causes genital disease. However, the
relative contribution of HSV-1 to genital
disease is increasing. With the exception
of neonatal herpes and herpes
encephalitis, HSV infections are seldom
life-threatening, nevertheless, the
disease causes significant physiological
and psychological distress,2 and
increases the risk of HIV infection.3
Data on the incidence and prevalence
of HSV in Australia are limited. A
seroprevalence study conducted among
antenatal and STD clinic attendees in
Sydney in the early 1990s found 5 and
14 per cent of women aged younger
than 20 years were HSV-2 positive
respectively.4 The prevalence increased
to 15.5 and 34 per cent in women aged
20–29 years. Estimates of the
seroprevalence of HSV-1 in adolescents
from several studies worldwide range
from 37 to 95 per cent.5 However, as in
adults, HSV infections are often
unrecognised and the magnitude of the
problem in adolescents is likely to be
underestimated.
There are no cures and the long-term
control of HSV would appear to be
reliant on prophylactic vaccines, early
detection and treatment, screening of
sexual contacts and appropriate
counselling. As the prevalence of
infection increases with age, control
strategies would appear to be
maximally effective if implemented
prior to sexual initiation.
Prophylactic vaccines are now in
development and current efforts focus
on two HSV envelope proteins,
glycoprotein B (gB) and D (gD). 
A gD candidate, developed by
GlaxoSmithKline Biologicals, has been
evaluated in two phase III efficacy
studies.6 The results suggest the vaccine
may prevent approximately 74 per cent
of genital herpes disease in women who
are seronegative for both HSV-1 and
HSV-2. While not statistically significant,
a trend towards protection against
infection was also observed in these
women (vaccine effectiveness: 39–46
per cent). There was no evidence of
vaccine efficacy in males, nor in women
who were HSV-1 seropositive. Further
efficacy studies are currently underway
to confirm these findings.
As part of an international
collaboration, the Vaccine &
Immunisation Research Group of the
Murdoch Children’s Research Institute
(located in the School of Population
Health at the University of Melbourne)
is evaluating the safety and
immunogenicity of this vaccine in 
10–17 year old females in Melbourne.
Other participating centres in
Australasia include Canberra, Sydney,
Brisbane, Hobart and Christchurch
(New Zealand). Participants are being
recruited predominantly through
schools and, in Melbourne, all study
visits are conducted in the participants’
homes. It is anticipated the study will
be concluded late in 2005. For further
information, contact Kerry-Ann O’Grady
on (03) 8344 9331 or at
k.ogrady@unimelb.edu.au.
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The Australian Community-
Acquired Pneumonia Study 
A new study on community-acquired
pneumonia (CAP) is starting in June
2004 and will be recruiting 1200 adult
patients over a 15-month period at
Austin Health, Monash Medical Centre,
Alfred Hospital, West Gippsland
Infectious diseases news
Hospital (Warragul), Royal Perth
Hospital and Princess Alexandra
Hospital (Brisbane). The Department of
Human Services, the National Health
and Medical Research Council and the
International Conference on
Chemotherapeutics Group are funding
the study.
The study has three key objectives. The
first is to examine the aetiology of CAP
in Australia. As such, this will be the
most extensive aetiology study
performed to date. New diagnostic
methods, such as polymerase chain
reaction for respiratory viruses and for
organisms causing atypical pneumonia
(Legionella, Mycoplasma and
Chlamydia) will be performed as well as
urinary antigens for Streptococcus
pneumoniae and Legionella. All patients
will have blood and sputum cultures,
and paired serology performed to look
for respiratory agents. All bacterial
isolates will be tested for resistance to
commonly used antibiotics.
The second objective is to examine
criteria for admission and systems for
severity assessments such as the
Pneumonia Severity Index (PSI)
proposed by Fine et al1 and the
Confusion, Urea, Respiratory rate and
Blood pressure (CURB-65) system
proposed by Lim et al .2 All patients
would have investigations performed
on admission to calculate their PSI and
CURB-65 scores. These proposed
severity assessment systems would be
validated for Australian patients and
attempts will be made to improve their
accuracy and their ability to predict
whether a patient requires care in a
ward or an intensive care unit.
The third objective of the study is to
prospectively validate the Australian
Antibiotic Guidelines.3 Patients enrolled
in the study would be treated with
empiric therapy according to the
guidelines. Outcomes assessed are
time to clinical stability and change to
oral therapy, clinical deterioration
requiring a change in therapy, need for
admission to an intensive care unit or
for mechanical ventilation, and
mortality at seven and 30 days.
The CAP study will be the largest study
of community-acquired pneumonia
ever undertaken in Australia and its
results will provide an evidence-based
approach to the treatment of CAP in
Australia for the next 10–20 years.
For further information about this study,
contact Dr Patrick Charles, Department
of Infectious Diseases, Austin Health.
Telephone: (03) 9496 6676. Email:
Patrick.Charles@austin.org.au
References: 
1 Fine MJ, Auble TE, Yealy DM, et al. A
prediction rule to identify low-risk
patients with community-acquired
pneumonia. N Engl J Med 1997;
336:243-50.
2 Lim WS, van der Eerden MM, Laing R,
et al. Defining community acquired
pneumonia severity on presentation to
hospital: an international derivation and
validation study. Thorax 2003; 58:377-
82.
3 Therapeutic Guidelines Limited.
Therapeutic Guidelines: Antibiotic. 12
ed. North Melbourne: Therapeutic
Guidelines Limited; 2003.
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Data cited in this report are based on
the Australian Childhood Immunisation
Register (ACIR) coverage report. Table 1
presents immunisation coverage at 31
March 2004 for children aged 12–<15
months, 24–<27 months and 72–<75
months at 31 December 2003.  Only
vaccines administered before 12 months
of age were included in the coverage
calculation for the first age group, and
only those vaccines administered before
24 months of age and 72 months of age
were included in the coverage
calculation for the second and third age
groups respectively.  
Additional explanatory note for the age
group 24–<27 months – Coverage
assessment for this age group has
changed from the December 2003
quarter to exclude the requirement for a
dose of diphtheria, tetanus and pertussis
antigens (DTP) at 18 months.  The
coverage calculation for this age group
now looks for a third or fourth dose of
DTP.  Prior to the change, the calculation
looked for the fourth dose only.  The
increase in coverage for this age group is
due to the less restrictive assessment,
requiring a child to be up-to-date for
vaccines at 12 months of age, when
assessed for coverage at 24–<27
months of age.
For a copy of the ACIR report listing
immunisation coverage against individual
vaccines for each local government area,
contact Michele Wend at the
Department of Human Services (email
michele.wend@dhs.vic.gov.au).
Table 1: Childhood immunisation coverage, by local government area, Victoria, March 2004
Age % fully Total LGAs
group immunised Local government area (LGA) (% LGAs)
12-<15 95+ Ararat (RC), Central Goldfields (S), Horsham (RC), Manningham (C), Mildura (RC), Mitchell (S), Moyne (S), 11 (14)
months Southern Grampians (S), Towong (S), Warrnambool (C), Whitehorse (C)
90-94 Alpine (S), Ballarat (C), Banyule (C), Boroondara (C), Brimbank (C), Buloke (S), Campaspe (S), Casey (C), Colac-Otway (S), 44 (57)
Corangamite (S), Delatite (S), East Gippsland (S), Frankston (C), Gannawarra (S), Greater Bendigo (C), Greater Geelong (C),
Greater Shepparton (C), Hindmarsh (S), Hume (C), Knox (C), Latrobe (C), Macedon Ranges (S), Maribyrong (C), Melton (S),
Monash (C), Moonee Valley (C), Moorabool (S), Moreland (C), Mornington Peninsula (S), Mount Alexander (S), Nillumbik (S),
Northern Grampians (S), Port Phillip (C), Pyrenees (S), Queenscliffe (B), Strathbogie (S), Swan Hill (RC), Wangaratta (RC),
Wellington (S), Whittlesea (C), Wodonga (RC), Wyndham (C), Yarra (C), Yarriambiack (S)
85-89 Bass Coast (S), Baw Baw (S), Bayside (C), Cardinia (S), Darebin (C), Glen Eira (C), Glenelg (S), Golden Plains (S), 19 (24)
Greater Dandenong (C), Hobsons Bay (C), Indigo (S), Kingston (C), Maroondah (C), Moira (S), Murrindindi (S),
South Gippsland (S), Stonnington (C), Surf Coast (S), Yarra Ranges (S)
80-84 Hepburn (S), Loddon (S), Melbourne (C), West Wimmera (S) 4 (5)
<80 Nil 0 (0)
24-<27 95+ Baw Baw (S), Buloke (S), Campaspe (S), Delatite (S), East Gippsland (S), Glenelg (S), Golden Plains (S), Hindmarsh (S), 25 (32)
months Horsham (RC), Indigo (S), Latrobe (C), Mildura (RC), Moorabool (S), Moyne (S), Northern Grampians (S), Pyrenees (S),
Queenscliffe (B), South Gippsland (S), South Grampians (S), Strathbogie (S), Towong (S), Wangaratta (RC),
Warrnambool (C), Wodonga (RC), Yarriambiack (S)
90-94 Alpine (S), Ararat (RC), Ballarat (C), Banyule (C), Bass Coast (S), Boroondara (C), Brimbank (C), Cardinia (S), Casey (C), 41 (53)
Colac-Otway (S), Corangamite (S), Darebin (C), Frankston (C), Gannawarra (S), Greater Bendigo (C), Greater Geelong (C),
Greater Shepparton (C), Hobsons Bay (C), Hume (C), Kingston (C), Knox (C), Loddon (S), Mecedon Ranges (S), Manningham (C),
Maribyronon (C), Maroondah (C), Melton (S), Mitchell (S), Moira (S), Moonee Valley (C), Mornington Peninsula (S), Mount
Alexander (S), Nillumbik (S), Stonnington (C), Surf Coast (S), Wellington (S), West Wimmera (S), Whitehorse (C), Whittlesea (C),
Wyndham (C), Yarra Ranges (S)
85-89 Bayside (C), Glen Eira (C), Greater Dandenong (C), Melbourne (C), Monash (C), Moreland (C), Murrindindi (S),
Port Phillip (C), Swan Hill (RC) 9 (11)
80-84 Central Goldfields (S), Hepburn (S), Yarra (C) 3 (4)
<80 Nil 0 (0)
72-<75 95+ Horsham (RC), Loddon (S), Moyne (S), Queenscliffe (B) 4 (5)
months
90-94 Baw Baw (S), Central Goldfields (S), Corangamite (S), Delatite (S), Gannawarra (S), Glenelg (S), Golden Plains (S), 13 (17)
Hindmarsh (S), Moira (S), Pyrenees (S), Wangaratta (RC), Warrnambool (C), Wyndham (C)
85-89 Ararat (RC), Ballarat (C), Boroondara (C), Brimbank (C), Campaspe (S), Cardinia (S), Darebin (C), East Gippsland (S), Frankston (C), 34 (44)
Glen Eira (C), Greater Bendigo (C), Greater Geelong (C), Greater Shepparton (C), Hobsons Bay (C), Hume (C), Indigo (S), Knox (C),
Manningham (C), Maroondah (C), Melton (S), Monash (C), Moonee Valley (C), Moorabool (S), Moreland (C), Murrindindi (S),
Nillumbik (S), South Gippsland (S), Southern Grampians (S), Wellington (S), West Wimmera (S), Whitehorse (C), Whittlesea (C),
Wodonga (RC), Yarriambiack (S)
80-84 Alpine (S), Banyule (C), Bayside (C), Casey (C), Greater Dandenong (C), Kingston (C), Latrobe (C), Macedon Ranges (S), 19 (24)
Maribyrnong (C), Mildura (RC), Mitchell (S), Northern Grampians (S), Stonnington (C), Strathbogie (S), Surf Coast (S),
Swan Hill (RC), Towong (S), Yarra (C), Yarra Ranges (S),
<80 Bass Coast (S), Buloke (S), Colac-Otway (S), Hepburn (S), Melbourne (C), mornington Peninsula (S), Mount Alexander (S), 8 (10)
Port Phillip (C)
Immunisation update
Catherine McNamara, Prevention and Perinatal Health Section,
Department of Human Services 
The Department of Human Services
receives notifications of infectious
diseases from medical practitioners and
laboratories. These notifications prompt
investigation and action to control
infectious diseases in Victoria. For some
diseases, investigation is initiated on the
basis of clinical suspicion in the
absence of laboratory confirmation.
Prompt notification of infectious
diseases is an integral component of
prompt public health action. Please do
not delay. To notify, call 1300 651
160 or fax 1300 651 170.
This section includes a summary of
infectious disease notifications received
until 31 March 2004. The
Communicable Diseases Section,
Department of Human Services,
produced the report in cooperation with
the Victorian Infectious Diseases
Reference Laboratory and the
Macfarlane Burnet Institute for Medical
Research and Public Health. We
gratefully acknowledge the contribution
of the Microbiological Diagnostic Unit of
the University of Melbourne and the
Melbourne Sexual Health Centre. 
Table 20 (page 54) includes historical
comparisons of selected diseases for
the period January - March 2004 with
2003 data at both state and regional
levels. Summary data at local
government level are available at the
website http://www.health.vic.gov.au/
ideas/surveillance/daily.htm. There
were no notifications of anthrax, Murray
Valley encephalitis, botulism, diphtheria,
Japanese encephalitis, Kunjin virus,
plague, poliomyelitis, rabies, viral
haemorrhagic fevers, yellow fever,
hepatitis D, leprosy, Haemophilus
Enteric diseases
Outbreaks of gastrointestinal
illness
Joy Gregory and Trang Vu, Department
of Human Services
In the first quarter of 2004, 34 outbreaks
of gastrointestinal illness were reported
to the department (Table 2). The
outbreaks occurred in a diverse range of
settings, including aged care facilities
(n=16), hospitals (n=4), commercial
caterers (n=3), private residences (n=2),
a play centre, a childcare centre, a
restaurant and on a bus trip. Three of
these outbreaks were considered to be
food borne or probably food borne.  Of
the remaining 31 outbreaks, 26 were
suspected to be transmitted by
person–to–person contact, with
norovirus accounting for 65 per cent
(n=17), rotavirus 8 per cent (n=2) and
suspected viral cause accounting for
27 per cent (n=7). The mode of
transmission was unknown for five
outbreaks. 
influenzae type b, rubella, tetanus or
Brucella in this reporting period. For
comments or queries related to the data
presented, contact the Communicable
Diseases Section (telephone 61 3 9637
4126). For HIV/AIDS enquiries, contact
Rebecca Guy or Dr Margaret Hellard,
Epidemiology and Social Research Unit,
Macfarlane Burnet Institute for Medical
Research and Public Health (telephone
61 3 9282 2290). 
Daily surveillance reports and weekly
commentary to assist with interpreting
these reports are available at the
website
http://www.health.vic.gov.au/ideas/su
rveillance/daily.htm. Data in this report
are provisional and subject to revision
as further information becomes
available. You can find general
information related to the control of
infectious diseases (The Blue Book) on
line at http://www.health.vic.gov.au/
ideas/bluebook/index.htm.
Surveillance report
Table 2: Outbreaks of gastrointestinal illness, Victoria, Jul–Sep 2003
Persons Pathogen/Toxin 
Setting Outbreaks Affected (Number of outbreaks)
Restaurant/reception/ 6 164 Salmonella Typhimurium 9 (1)
other food premises/ Norovirus (1)
specific food Unknown (4)
Aged/disability/ 23 459 Norovirus (14)
health care institution Suspected viral (7)
Unknown (2)
Recreation/holiday/camp 2 21 Norovirus (1)
Rotavirus (1)
Children’s service/school 1 30 Rotavirus (1)
Family/social gathering 2 22 Norovirus (2)
TOTAL 34 696 Norovirus (18)
Salmonella Typhimurium 9(1)
Suspected viral (7)
Rotavirus (2)
Unknown (6)
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An outbreak of Salmonella
Typhimurium phage type 170 linked
to a hotel in a northern suburb
On 31 December 2003, the
department was notified of two cases
of Salmonella infection with the
suspected mode of transmission being
food consumed at the hotel. Both
cases were interviewed to obtain
further information. A third case, who
had shared food with one of the
notified cases, was also interviewed.
On 5 January 2004, the department
received a notification of salmonellosis
for the third case.
The department conducted an
investigation through case interviews,
active case finding from laboratory line
lists and telephone contact with other
patrons of the hotel. Initial interviews
suggested a possible link between
illness and the consumption of dishes
containing raw egg ingredients made at
the premises, for example chocolate
mousse, mayonnaise and tartare
sauce. The use of raw egg ingredients
has been associated with several
Salmonella outbreaks in Australia and
overseas.1,2 A cohort study was
designed to test the hypothesis that
patrons who had dined at the hotel on
23, 25 or 28 December 2003 and
consumed food containing raw egg
ingredients were more likely than those
who had not consumed such food to
develop gastrointestinal illness in the
five days following their attendance.  
The cohort study commenced on 9
January 2004 and concluded on 23
January 2004. The minimum sample
size required for the study was
estimated to be 100 persons. Twenty-
four contactable groups were randomly
selected from the hotel’s booking lists
to provide 141 potential study
participants.  Of these potential
participants, 9 per cent (n=13) were
subsequently determined to be
ineligible to take part in the study
because of booking cancellations. At
the conclusion of this study 108 people
were interviewed giving the study a
participation rate of 84 per cent.
Of 108 people interviewed, 23 per cent
(n=25) had gastrointestinal symptoms
(diarrhoea and/or vomiting in the six
hours to five days following
consumption) and 64 per cent (n=69)
dined on Christmas day. Among those
experiencing illness, 96 per cent (n=24)
ate on Christmas day. Salmonella
Typhimurium phage type 170 (STM 170)
was isolated in the faecal specimens of
four ill persons.  
The study found that patrons who had
consumed food containing raw egg
ingredients were seven times more likely
to become ill. Furthermore, only 8 per
cent (n=2) of ill cases had eaten food
not containing raw egg ingredients. The
results suggest a possible association
between illness and the consumption of
any food containing raw egg ingredients.
As no food sample collected for culture
was found to be positive for STM 170,
this observed association could not be
confirmed. 
The department recommended to the
hotel that they stop serving dishes or
sauces containing ingredients made
from raw eggs. The hotel has since
changed their practices from producing
their own sauces and desserts (such as
tartare, mayonnaise and mousse) to
purchasing pre-made mousse mixtures
and commercial mayonnaise. 
References
1 OzFoodNet Working Group. Foodborne
disease in Australia: incidence,
notifications and outbreaks. Annual
report,OzFoodNet, 2002. 
2 Centre for Disease Control.
Surveillance for Foodborne-Disease
Outbreaks —United States, 1993–1997.
CDC Surveillance Summaries. MMWR
2000;49(No. SS-1)
An outbreak of Clostridium
perfringens in a rural hospital
In February 2004, the department
became aware of an outbreak of
gastrointestinal illness affecting 14
residents in the aged care unit of a
rural hospital. The residents
experienced offensive diarrhoea over a
two-day period, however, none
reported nausea or vomiting. No staff
members or patients in other wards
reported any symptoms. Five faecal
specimens were collected for
laboratory investigation. Of these
specimens, four were negative for
bacterial pathogens while one had
heavy growth of Clostridium perfringens
but no enterotoxin was detected.
This outbreak was consistent with a
point source outbreak of Clostridium
perfringens, based on the tight
clustering of onsets, the pattern of
symptoms and the short duration of
the outbreak. Investigations by the
department found that the aged care
unit took delivery of main meals
prepared by the cook-chill method from
a neighbouring hospital and re-heated
in a microwave before serving. An
inspection of the food safety program
at this hospital revealed that the
program did not cover the cook-chill
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method because this method was
introduced just before the outbreak.
The local council supervised a clean-up
at the hospital and at the cook-chill
kitchen.
Bloodborne viruses
Hepatitis B
Megan Counahan, Department of
Human Services
There were 24 cases of acute hepatitis
B infection notified in the first quarter
of 2004.This represents a 46 per cent
decrease in the number of notifications
received for the same period in 2003.
The decrease returns the number of
cases notified in Victoria to those
reported in 2000 (n=19) prior to the
sudden increase of cases seen in
2001.  Fifty-eight per cent of
notifications were for females (n=14).
The age of cases ranged from 15 to 73
years.  There were no notifications for
people identified as Aboriginal and/or
Torres Strait Islander.  
Hepatitis C
Luke Atkin, Department of Human
Services
Between 1 January and 31 March
2004, the department received a total
of 782 notifications of hepatitis C
infection, compared with 979
notifications for the same period in
2003. Of the 782 notifications, 16
cases (two per cent) were classified as
newly acquired.  It should be noted
that the number of newly acquired
cases probably under-represents the
burden of newly acquired hepatitis C in
Victoria. Due to the nature of the
disease and the risk behaviour
associated with it, the probability of
obtaining better data on the newly
acquired cases is limited. 
Newly Acquired Hepatitis C 
Of the 16 newly acquired cases, seven
were male and nine were female. The
median age for both males and females
was 27 years (range: 17–43 years for
males, 17–36 for females). Eight cases
(50 per cent) were diagnosed on the
basis of seroconversion to hepatitis C
virus in the previous 24 months, five
(31 per cent) were diagnosed on the
basis of having had clinical hepatitis in
the previous 24 months and three were
diagnosed on the basis of having both
laboratory and clinical evidence. 
Injecting drug use was the major risk
factor reported (n=14 or 88 per cent).
Other risk factors identified through
Figure 2: Notifications of hepatitis C not further specified, by region and
per 100,000, Victoria, January–March 2004
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Figure 3:  Notifications of hepatitis C not further specified, by age group
and sex, and per 100,000, Victoria, January–March 2004
N
o.
 o
f n
ot
ifi
ca
ti
on
s
Pe
r 1
00
,0
00
0
10
20
30
40
50
60
70
80
90
60
+
55
–5
9
50
–5
4
45
–4
9
40
–4
4
35
–3
9
30
–3
4
25
–2
9
20
–2
4
15
–1
9
10
–1
4
5–
9
0–
4
0
5
10
15
20
25
30
35
40
Age group (years)
Female
Male
Rate
Victorian Infectious Diseases Bulletin Volume 7 Issue 2 September 2004 43
follow-up were imprisonment (n=1),
having a hepatitis C positive sexual
partner (n=2), having a household
contact (n=1), surgery (n=1) and
tattooing (n=1).  Cases may have more
than one risk factor identified.  The
case with surgery reported as a risk
factor is currently being investigated.
Hepatitis C (not further specified)
Of the 782 notifications of hepatitis C,
766 (98 per cent) were classified as not
further specified (NFS). Of these, 444
were male, 319 were female and sex
was not stated for three notifications.
The highest notification rates were in
the western metropolitan region 
(Figure 2). The number of notifications
and notification rates per 100, 000
population, by age group and sex are
depicted in Figure 3.
Vaccine-preventable
diseases
Invasive pneumococcal disease 
Megan Counahan, Department of
Human Services
There were 71 cases of invasive
pneumococcal disease (IPD) notified in
the first quarter of 2004.  This
represents a three per cent increase on
the number of cases for the same
period in 2003 (n=69).  The age range
of those notified was 3 months to 91
years.  Two persons were identified as
Aboriginal and/orTorres Strait Islander.
Fifty-eight per cent of notifications
were for males (n=41), 42 per cent
(n=30) were for females.  Three deaths
were reported as attributed to IPD in
the quarter: two were aged over sixty
five (case fatality rate =  9 per cent)
and one aged under five years (case
fatality rate = 5 per cent).  All but one
of these (73 year old male) were
unvaccinated. 
Serotype information was available on
89 per cent (n=63) of cases.  All cases
in children aged under two years and
83 per cent of those aged between two
and five years were of a serotype
contained in the seven valent
conjugate vaccine, however, these
cases were unvaccinated.  Of those
aged over 65 years, 86 per cent were
of a serotype contained in the 23
valent vaccine.  There were six cases,
all in persons over 50 years of age, who
had been vaccinated and their
acquisition of IPD was likely to be
attributed to vaccine failure.  
Other notifiable diseases
Tuberculosis
Lynne Brown, Department of Human
Services
Owing to the slow growing nature of
Mycobacterium tuberculosis, data are
preliminary and subject to change. This
report relates to notifications for the
first quarter of 2004, from 1 January to
31 March 2004.
Overview
There were 83 notifications of
tuberculosis to the department in the
first quarter of 2004—an increase of 14
per cent on the notifications for the
same period in 2003. Of the 83
notifications, 39 were for females (47
per cent) and 44 (53 per cent) were for
males. Patients aged 20–24 years and
25–29 years had the highest
notification rates at 4.5 and 3.9 per
100,000 respectively (Figure 4). Three
children aged under 15 years were
notified—all were identified by contact
tracing and found to have early signs of
disease on initial assessment.
Eighty-four percent (n=70) of
notifications were for overseas born
persons. Of these notifications, a total
of 32 were born in India (14), Vietnam
(10) or China (8). There were no
notifications for persons identified as
Aboriginal and/orTorres Strait Islander.
Thirteen (19 per cent) of the 70
overseas born persons had previously
Figure 4: Notifications of tuberculosis, by age group and per 100,000,
Victoria, January–March 2004
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been placed on a Tuberculosis
Undertaking (TBU) that requires a new
migrant to undergo further screening
and assessment for possible
tuberculosis on arrival in Australia. Six
of these cases (46 per cent) were
diagnosed on the basis of the health
assessment required as a condition of
theirTBU. One patient was known to
have HIV and TB co-infection.
Pulmonary disease accounted for forty-
five per cent of all notifications (n=37)
(Table 3). Five of these notifications
noted additional sites, other than the
lungs (Table 4). Pleural disease was the
most common additional site, however,
one case had pharyngeal tuberculosis
and a second had disseminated
disease. Extra pulmonary disease was
reported in 55 per cent of notifications—
the most common sites being lymphatic
(57 per cent), bone/joint (12 per cent)
and pleural (14 per cent). Of the 29
lymph node notifications, six were
mediastinal nodes and three were hilar
lymphadenopathy. The latter were
identified in children and is usually
indicative of recent infection and/or
primary disease.
Laboratory confirmation (smear, culture
or antigen detection) was obtained in
86 per cent of notifications (Table 5).
Seventy per cent were confirmed by
culture. Specimens for laboratory
confirmation were submitted for 89 per
cent of pulmonary notifications and the
diagnosis was bacteriologically
confirmed in 73 per cent of these
notifications. Less than half (15 of 37)
of the pulmonary notifications were
smear positive for acid-fast bacilli
whereas 73 per cent (27 of 37) were
positive on culture. Five patients with
culture negative results remained on
anti-tuberculosis treatment on the
basis of radiological changes. 
For seventy-nine cases, no past history
of tuberculosis treatment was reported.
Four had a past history of either full or
partial treatment in Australia or
overseas. However, two cases who
reportedly had been fully treated were
culture negative and therefore did not
meet the case definition for a relapse
of tuberculosis.  
Legionellosis 
Megan Counahan, Department of
Human Services
Twenty-four cases of confirmed or
probable legionellosis were notified in
the first quarter of 2004 compared with
29 in the same period in 2003. Twelve
(50 per cent) were for Legionella
pneumophila species with eight of these
(67 per cent) being L. pneumophila
serogroup 1. Ten cases (42 per cent)
were caused by Legionella longbeachae
and the remaining two cases (8 per
cent) were L. micdadei.  Fourteen (58
per cent) notifications were for males
and 10 (42 per cent) were for females.
Table 3: Notifications of
tuberculosis, by site of disease,
Victoria, January–March 2004
Site Number
Pulmonary 32
Pulmonary and other sites 5
Lymph nodes 29
Pleural 7
Bone/joint 6
Genito/urinary 1
Meningeal 1
Other 7
Total 88
Note: Total is greater than number of
notifications due to multiple sites in some
patients.
Table 5: Laboratory confirmation of tuberculosis notifications, by
diagnostic method, Victoria, January–March 2004
Diagnostic Extra pulmonary Pulmonary Pulmonary Total
Method tuberculosis only tuberculosis only tuberculosis 
plus other sites
Clinical signs 1 1
Radiology 4 6 1 11
Microscopy 3 2 5
Culture 33 23 4 60
Histology 4 1 5
PCR/NAT* 1 1
Total 46 32 5 83
*PCR/NAT: polymerase chain reaction/nucleic acid testing
Table 4 : Additional sites of
infection associated with
notifications of pulmonary
tuberculosis, Victoria,
January–March 2004
Site Number
Pleural 2
Bone/joint 1
Lymph nodes 1
Other 1
Total 5
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The age range of cases was 25–89
years.  There were two deaths
attributed to the disease during the
reporting period—an 89-year-old male
with L. pneumophila serogroup 1 and a
53-year-old female with L. longbeachae. 
The department investigated two
outbreaks in the first quarter. One
occurred in a south-eastern suburb and
involved three cases, however, no
source was identified.  The other
outbreak in inner Melbourne involved
two cases and no confirmed source
was identified. 
Invasive Meningococcal
Disease
Megan Counahan, Department of
Human Services
There were 21 confirmed or probable
cases of invasive meningococcal
disease notified in the first quarter of
2004 compared with 28 for the same
period in 2003.  Of the 21 cases, 10
(48 per cent) were female and 11 (52
per cent) were male.  Forty-three per
cent (n=9) were Group B disease, 19
per cent (n=4), were Group C disease,
9 per cent (n=2) Group Y, and the
remaining cases were people with
either a clinically compatible illness
(n=4) or an isolate which was not
further typed (n=2).  
There was one death attributed to
Group C disease in a 71 year-old
woman.  There were no cases of Group
C disease notified among the age
groups eligible for free vaccine under
the National Meningococcal C
Immunisation Programme (refer to
shading area in Table 6 above).
Sexually transmissible
infections
Human Immunodeficiency
Virus (HIV) Infection
Rebecca Guy, Macfarlane Burnet
Institute for Medical Research and
Public Health
There were 55 new HIV diagnoses in
Victoria during the first quarter of
2004. This is identical to the number
reported in the previous quarter, but a
five per cent increase on the 52 in the
same quarter in 2003 (Figure 5). The
median age of cases for this quarter
was 36 years (range: 3–63 years). 
Of the 55 new HIV diagnoses this
quarter, 50 were in males, four were in
females and one was in a transgender
individual (Table 7). Of the 50 males,
40 (80 per cent) reported male-to-male
sexual contact as their exposure
category (Table 8)–a seven per cent
decrease on the 43 reported in the
previous quarter. Of these 40 males,
33 (83 per cent) reported having
acquiring their infection in Victoria
(Table 9). Also in this group, HIV
infection was reportedly acquired from
an anonymous partner for 23 per cent,
a casual partner for 28 per cent and a
regular partner for 15 per cent. Table
10 shows a breakdown of other
options reported for source partner
type.
Heterosexual Contact
Of the 55 new HIV diagnoses this
quarter, five (three males, two females)
reported heterosexual contact as their
exposure category (Table 11). Of these
five, four (80 per cent) were born in a
high prevalence country or reported
Table 6: Notifications of invasive meningococcal disease serogroups B
and C, by vaccination program age group, Victoria, 1997–2004
Meningococcal Age group
disease (years) 1997 1998 1999 2000 2001 2002 2003 2004
Group B <1 0 0 0 0 0 0 1 1
1–5 3 2 1 1 5 1 2 0
6–14 1 0 1 3 1 0 1 1
15–19 2 1 1 3 4 2 1 2
20–30 1 1 1 1 2 4 1 2
30+ 1 0 1 2 0 1 1 3
Subtotal 8 4 5 10 12 8 7 9
Group C <1 0 0 0 0 0 0 0 1
1–5 0 0 0 2 1 0 2 0
6–14 0 0 0 1 3 1 0 0
15–19 1 0 0 4 1 5 4 0
20–30 1 2 1 4 3 3 2 0
30+ 0 0 1 2 6 2 5 3
Subtotal 2 2 2 13 14 11 13 4
Total Total 10 6 7 23 26 19 20 13
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heterosexual contact with a person
from a high prevalence country.
Injecting Drug Use (IDU)
In the first quarter of 2004, eight
notified cases had a history of injecting
drug use and six of these also reported
male-to-male sexual contact (Table 8). 
Sex Workers
Two cases (one male, one transgender)
were identified as sex workers with both
reported a history of male sex work. 
Other Exposure Categories
One female aged three years had her
HIV status confirmed in 2004. This
child acquired her infection in the first
few months of life through being
breastfed but at the time her HIV test
results did not meet the HIV case
definition. The mother of this child
acquired HIV through heterosexual
contact post-delivery.
Incident Infections
Those with newly acquired HIV or
incident infection provide a picture of
Figure 5: HIV diagnoses by year and quarter, Victoria, 1999–2004
N
o.
 o
f H
IV
 d
ia
gn
os
es
0
50
100
150
200
250
200420032002200120001999
Quarter 4
Quarter 3
Quarter 2
Quarter 1
Table 7: New HIV diagnoses by age group, Victoria, January–March 2004
and January–December 2003
Age group Jan–March 2004 Jan –Dec 2003
(years) Male Female Transgender Total Male Female Total
0–12 0 1 0 1 0 0 0
13–19 0 0 0 0 3 1 4
20–29 11 3 0 14 47 4 51
30–39 21 0 1 22 88 10 98
40–49 13 0 0 13 40 3 43
50-59 3 0 0 3 21 1 22
60+ 2 0 0 2 7 0 7
Total 50 4 1 55 206 19 225
Table 8: New HIV diagnoses, by exposure category, Victoria, January–March 2004 and January–December 2003
Exposure Category Jan–March 2004 Jan–Dec 2003
Male Female Transgender Male Female
n % n % n % n % n %
Male homosexual/bisexual 40 80 – – 0 0 163 79 – –
Male homosexual/bisexual and injecting drug user 5 10 – – 1 100 10 5 – –
Injecting drug user 2 4 0 0 0 0 8 4 2 11
Heterosexual 3 6 0 0 0 0 16 8 10 53
Person from a HPC* 0 0 2 50 0 0 6 3 7 37
Haemophilia/related disorder 0 0 0 0 0 0 0 0 0 0
Transfusion recipient 0 0 1# 25 0 0 0 0 0 0
Other/unknown 0 0 1 25 0 0 3 2 0 0
Total 50 100 4 100 1 100 206 100 19 100
* HPC: high prevalence country (greater than one per cent of population infected with HIV).
# Overseas acquisition.
Victorian Infectious Diseases Bulletin Volume 7 Issue 2 September 2004 47
who is presently affected by the HIV
epidemic. Such individuals are
identified on the basis of a previous
negative HIV test and/or a
seroconversion illness within the 12
months preceding HIV diagnosis. 
Fifteen individuals (14 males, one
transgender) were classified as incident
HIV infections during the first quarter of
2004 (Table 12)–a 12 per cent decrease
on the 17 incident infections identified
in the previous quarter.
Acquired Immune Deficiency
Syndrome
There were ten notifications of AIDS
during the first quarter of 2004 (nine
males, one female) and six individuals
had been diagnosed with AIDS within
this time frame. Of the nine males,
eight (89 per cent) reported a history of
male-to-male sexual contact. 
Deaths
There were three deaths following HIV
or AIDS diagnosis notified during the
first quarter of 2004, compared to
seven deaths in the previous quarter.
All deaths were among males.
Chlamydia Infections
Luke Atkin, Department of Human
Services
Summary of total notifications
The department received 1997
notifications of Chlamydia trachomatis
in the first quarter of 2004, representing
a 31 per cent increase on the number of
notifications for the same period in
2003 (n=1529) (Figure 6). The age and
sex distributions remain unchanged
with the greatest burden of disease in
the age group 20 –24 years. The
Table 9: New HIV diagnoses in males reporting homosexual contact, by
place where infection was acquired, Victoria, January–March 2004 and
January–December 2003
Place Infection Jan–March 2004 Jan–Dec 2003
Acquired n % n %
Victoria 33 82.5 117 71.8
Interstate 2 5.0 14 8.6
Overseas 1 2.5 21 12.9
Unknown 4 10.0 11 6.7
Total 40 100 163 100
Table 10: New HIV diagnoses in males reporting homosexual contact,
by source partner type, Victoria, January–March 2004 and
January–December 2003
Source Partner type Jan–March 2004 Jan–Dec 2003
n % n %
Regular partner 6 15.0 26 16.0
Casual partner 11 27.5 50 30.7
Anonymous Partner 9 22.5 45 27.6
Any combination of above 8 20.0 17 10.4
Unknown 6 15.0 25 15.3
Total 40 100 163 100
Table 11: New HIV diagnoses reporting heterosexual exposure, Victoria,
January–March 2004 and January–December 2003.
Exposure Category Jan–March 2004 Jan–Dec 2003
Male Female Male Female
n % n % n % n %  
Person from a HPC*  0 0.0 2 100.0 6 27.3 7 41.1
Heterosexual contact with 
person from a HPC* 2 66.7 0 0.0 6 27.3 2 11.8  
Heterosexual contact with 
bisexual man 0 0.0 0 0.0 0 0.0 2 11.8  
Heterosexual contact with IDU 0 0.0 0 0.0 1 4.5 1 5.9
Heterosexual contact with 
person with HIV 0 0.0 0 0.0 1 4.5 3 17.6
Heterosexual contact with 
person with other risk 0 0.0 0 0.0 0 0.0 0 0.0
Heterosexual contact
(not otherwise specified) 1 33.3 0 0.0 8 36.4 2 11.8
Total 3 100 2 100 22 100 17 100
* HPC: high prevalence country (greater than one per cent of population infected with HIV).
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Figure 6: Notifications of Chlamydia, by quarter, Victoria, 1999–2004
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Figure 7: Notifications of Chlamydia, by department region and per
100,000, Victoria, January–March 2004
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Table 12: New HIV diagnoses, by time since last negative test or
seroconversion illness, January–March 2004 and January–Dec 2003.
Time between HIV diagnosis Jan–March 2004 Jan–Dec 2003
and negative test and/or
seroconversion illness Male Female Transgender Male Female
Less than one year 14 0 1 70 4
One year to less than three years 9 0 0 28 2
Three or more years 10 0 0 28 3
No previous negative test or
seroconversion illness 13 4 0 80 10
Unknown 4 0 0 0 0
Total 50 4 1 206 19
highest number of notifications was
from the southern metropolitan region,
while the highest notification rate was
from the western metropolitan region
(Figure 7).
Data on the type of specimen and
laboratory testing methods were
available for 1709 (86 percent)
notifications (Table 13). Nucleic acid
tests were the most common method
reported.  No laboratory confirmation
was received for 287 (14 percent)
notifications compared with 99 (5
percent) of notifications in the previous
quarter. The Medicare Benefits
Schedule does not fund testing for
more than one site per episode, so the
surveillance system is likely to
underestimate the true number of
extragenital infections.
The passive notification system is
enhanced by the collection of risk
factor information from clinicians.
There were 717 (36 per cent)
questionnaires returned for the first
quarter 2004 (although not all
questionnaires were complete),
compared with 620 (40 per cent) for
the same period in 2003. Table 14
outlines case characteristics of the
population for whom enhanced
surveillance information was available.
According to enhanced data, the most
common reason reported for Chlamydia
testing was clinical evidence of a
sexually transmissible infection 
(n = 240) (Table 15). Patient initiated
screening was the next most common
reason for testing (n = 228), followed by
doctor initiated screening (n = 117).
Cases diagnosed as a result of
antenatal screening comprised a small
proportion of notified cases (n = 2).
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Gonorrhoea
Luke Atkin, Department of Human
Services
There were 315 notifications of
Neisseria gonorrhoeae in the first
quarter of 2004, compared with 294
notifications for the same period in
2003 (Figure 8). Of the notifications in
the first quarter, 285 (90 per cent)
were for males and 30 (10 per cent)
were for females.  The median age was
33 years for males (range: 0–70 years)
and 36 years for females (range:
16–62 years). Table 16 details the age
and sex distributions of the
notifications for which gender was
reported.
The region of residence was known for
77 per cent (n=242) of the gonorrhoea
Table 13: Specimen type and laboratory testing method for
C. trachomatis, Victoria, January–March 2004
Specimen type Specimen site Laboratory testing method Total
Culture NAT/PCR* Not Stated
Swab Cervix 2 510 1 513
Eye 0 14 0 14
Pharynx 0 2 0 2
Rectum 1 39 0 40
Urethra 0 136 0 136
Vagina 1 96 0 97
Not specified 1 36 0 37
Urine Not applicable 6 934 1 941
Other 0 3 0 3
Not stated 0 43 0 43
* NAT/PCR: nucleic acid testing/polymerase chain reaction. 
May include multiple testing on a single individual
Table 15: Enhanced data on reported reasons for testing for Chlamydia,
Victoria, January–March 2004
Reason for testing Female Male Gender not stated Total
Clinical evidence of STI 96 144 0 240
Patient initiated STI screen 120 107 1 228
Doctor initiated STI screen 77 40 0 117
Asymptomatic contact* 42 38 0 80
Abnormal examination 7 0 7
Pre-termination screen 4 0 0 4
Antenatal screen 2 Not applicable 0 2
Other 24 5 0 29
Not stated 5 5 0 10
Total 377 339 1 717
*Contact with a known infected partner
Table 14: Enhanced
epidemiological data on
Chlamydia notifications, Victoria,
January–March 2004
Male Female Not Total
Stated
Gender of reported sexual partner
Male 79 336 0 415
Female 230 9 0 239
Unknown/
not stated 30 32 1 63
Total 339 377 1 717
Partner type
Regular partner 114 202 0 316
Casual partner 172 112 0 284
Client 0 0 0 0
Sex worker 1 2 0 3
Unknown/
not stated 52 61 1 114
Total 339 377 1 717
Where infection acquired
Victoria 253 311 0 564
Interstate 16 6 0 22
Overseas 26 17 0 43
Unknown/
not stated 44 43 1 88
Total 339 377 1 717
cases. Notification rates were highest
in the metropolitan regions with the
highest notification rates in the
western metropolitan region (Figure 9).
The notifying clinician provides the
department with risk factor information
on the case.  Enhanced surveillance
information was obtained for 79 per
cent (n =248) of notifications, although
not all questionnaires were complete.
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and 8 per cent (n=18) the information
was either unknown or not stated. 
For the 222 male cases of whom the
information was collected on partner
type, 69 percent (n=153) reported
having acquired their infection from a
casual partner, while 19 per cent
(n=42) reported acquisition from a
Males
Of the 285 notifications for males,
information on the sexual partner was
collected for 222 cases (78 per cent).
For 70 per cent (n=156), a male
partner was reported; for 22 per cent
(n=48), a female partner was reported,
Figure 8: Notifications of gonorrhoea, by yearand quarter,Victoria, 1999–2004
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regular partner, 2 per cent (n=5)
reported acquisition from a sex worker
and 1 per cent (n=2) reported
acquisition from a client.  For 9 per
cent (n=20) the information was either
unknown or not stated.
Of the 222 male cases for whom
information was collected on the place
of acquisition of infection, 81 per cent
(n=179) reported having acquired their
infection in Victoria.  The place of
acquisition was reported as being
overseas for 8 per cent (n=18), and
interstate for 4 per cent (n=9) and
unknown for seven per cent.
Females
For the 30 female cases, the gender of
the sexual partner was collected for 90
per cent (n=27).  Of these, 96 per cent
(n=26) reported having acquired their
infection from a male partner. The
gender of the partner was unknown for
one case. 
For the 27 female cases of whom
information was collected on partner
type, 56 per cent (n=15) reported
having acquired their infection from a
regular partner, while 30 per cent (n=8)
reported acquisition from a casual
partner. One case reported having
acquired the infection from a client. For
three notifications the partner type was
reported as unknown or not stated.
Information about the place of
acquisition of infection was collected
from 27 of the female cases.  The
majority of infections were acquired in
Victoria (74 per cent, n=20) while two
infections were reported as being
acquired overseas.  The place of
acquisition was unknown or not stated
in five cases.
Table 16: Notifications of gonorrhoea, by age group and sex, Victoria,
January–March 2004, January–December 2003 and January–December
2002
Jan–Mar 2004 Jan–Dec 2003 Jan–Dec 2002
Age group Male Female Total Male Female Total Male Female Total
0-4 1 0 1 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 2 2 4 2 1 3
15–19 18 2 20 37 16 53 18 10 28
20–24 49 5 54 147 23 170 101 16 117
25–29 52 5 57 221 13 234 137 14 151
30–34 44 3 47 213 12 225 158 12 170
35–39 49 5 54 176 5 181 132 6 138
40–44 30 1 31 129 9 138 82 5 87
45–49 17 1 18 50 4 54 44 2 46
50–54 10 4 14 35 6 41 24 2 26
55–59 11 3 14 36 5 41 21 1 22
60 + 4 1 5 13 0 13 12 2 14
Total 285 30 315 1059 95 1154 731 71 802
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The most common site of a positive
test was the urethra (Table 17). Testing
for antibiotic susceptibility is currently
only possible if N. gonorrhoeae is
isolated by culture.  Of the 315
notifications, 250 isolates (79 per cent)
were tested for antibiotic susceptibility
by the Microbiological Diagnostic Unit.
Of these, 227 were from males and 23
from females.  Multiple isolates can be
tested from each individual.
Resistance to ciprofloxacin was
identified in 85 (34 per cent) of 250
isolates.  Of the 116 isolates collected
from male cases that reported a male
sexual partner and having acquired
their infection in Victoria, 28 per cent
(n=32) were ciprofloxacin resistant,
compared with thirty four per cent from
the last quarter of 2003.  The
department recently updated the
gonorrhoea fact-sheet recommending
treatment of all gonorrhoea infections
with ceftriaxone and placed alerts with
the Victorian Divisions of General
Practice
Infectious Syphilis
Luke Atkin, Department of Human
Services
In the first quarter of 2004, there were
19 cases of infectious syphilis, sixteen
being male and three female.  This
represents a 111 per cent increase on
the nine cases notified in the fourth
quarter of 2003 (six males, three
females) and a 90 per cent increase on
the ten cases notified in the first
quarter of 2003 (all male) (Figure 10).  
Figure 9:  Notifications of gonorrhoea, by department region and per
100,000, January–March 2004
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Table 17: Positive N. gonorrhoeae
tests, by site of infection, Victoria,
January–March 2004
Specimen Specimen Number
type site
Blood Not applicable 1
Swab Cervix 6
Eye 0
Pharynx 26
Rectum 39
Urethral 143
Vagina 8
Not specified 8
Urine Not applicable 48
Not stated Not stated 41
Total 320
Figure 10: Infectious syphilis notifications, by year and quarter, Victoria,
1999–2004
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Of the 19 cases, seven were primary
infections, five were secondary
infections, six were early latent
infections, and one was a case of
neurosyphilis.  The median age was 36
years (range: 20–53 years).
Males
Of the sixteen male cases, thirteen
reported male sexual partners, one
reported a female sexual partner, one
reported a transgender partner and for
one case the information was not
stated. Twelve male cases reported
acquiring their infection from a casual
partner, two cases reported acquiring
their infection from a regular partner,
one case reported acquiring their
infection from a sex worker and for one
case the information was unknown. Of
the sixteen males, nine reported
acquiring their infection in Victoria,
three overseas, three interstate and for
one case the information was
unknown.
Females
Of the three female cases, one
reported a male sexual partner, for one
case the information was unknown and
for one case the information was not
stated.  One of the female cases
reported acquiring her infection from a
regular partner and for the remaining
two cases the information was
unknown. Of the three females, two
reported acquiring their infection
overseas, and for one the information
was unknown.
Bloodstream infections and
meningitis
Sally Bodenham and MarkVeitch,
Microbiological Diagnostic Unit, the
University of Melbourne.
Surveillance case definitions
An episode of bacteraemia or
meningitis is defined as the first
isolation of a clinically significant
bacterium or fungus from the blood or
cerebrospinal fluid (CSF) of a person in
a 14-day period. Persons having more
than one species of bacteria or fungi
isolated are counted as different
episodes. We include recent historical
averages and counts for comparison.
These are based on slightly different
case definitions and so serve only as a
general guide to trends. An organism
may sometimes be reported by the
diagnostic laboratory only to the genus
level or may be incompletely speciated
(where definitive identification is
unnecessary for patient care).
Therefore, some organism categories,
such as coagulase-negative
Staphylococcus and Staphylococcus
epidermidis, overlap. 
Summary of important causes of
bloodstream infection (BSI) and
meningitis in the first quarter of
2004
There were 1212 reports of BSI and
meningitis caused by 117
species/types bacteria and fungi for
the first quarter of 2004. Of these
reports, 1200 were from BSI and 12
were from meningitis. Twenty
organisms accounted for 82 per cent of
reports (Table 18). 
The increase in reports of
Acinetobacter calcoaceticus–baumanii
complex and Serratia marsescens was
mostly attributable to localised clusters
of cases. Cases of Streptococcus bovis
were not clustered and may represent
random variation in counts. 
Trends in antimicrobial resistance of
some invasive bacterial pathogens 
The patterns of resistance to key
antimicrobials in invasive isolates of
Gram positive pathogens and E. coli
during the first quarter of 2004 were
similar to those seen in the previous
four years.1 The proportion of S. aureus
isolates reported to be resistant to
methicillin for the first quarter of 2004
was 29 per cent
(Table 19). The proportion of isolates
demonstrating methicillin resistance
was 19 per cent among specimens
collected before the third day of
hospitalisation, rising to 55 per cent
among specimens collected after the
seventh day of hospitalisation. Five per
cent (three isolates) of invasive 
S. pneumoniae were reported as
intermediate or resistant to penicillin.
None were reported as non-susceptible
to cefotaxime/ceftriaxone.
Invasive infections caused by 
E. faecalis were more common than
those due to E. faecium, but were less
likely to be due to vancomycin resistant
isolates. Vancomycin resistance was
reported in 22 per cent (two isolates) of
E. faecium, and three per cent (one
isolate) of E. faecalis. All three isolates
had the vanB gene detected by
polymerase chain reaction.
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Reports of the susceptibility of
Escherichia coli isolates to
aminopenicillins, ceftazidime,
gentamicin and ciprofloxacin were
available for 97 per cent, 66 per cent,
98 per cent and 83 per cent of isolates
respectively. The proportion of E. coli
isolates resistant to aminopenicillins
was 40 per cent, while the proportion
resistant to ciprofloxacin, ceftazidime
or gentamicin was low (each less than
or around 3 per cent). 
Reference
1 Bodenham S & Veitch M. Surveillance
of bloodstream infections and
meningitis in 2003 by the Victorian
Hospital Pathogens Surveillance
Scheme. Victorian Infectious Diseases
Bulletin 2004;7(1):7-9.
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Table 18: The twenty most common isolate types reported to VHPSS,
Victoria, January–March 2004.
Isolate type Jan–Mar Three year 2004 2003 2003
2004 mean ytd ytd total
(2001–03)
Escherichia coli 272 246 272 229 939
Staphylococcus aureus 257 240 257 232 938
Klebsiella pneumoniae 69 54 69 56 212
Streptococcus pneumoniae 64 71 64 76 446
Coagulase negative Staphylococcus 57 50 57 51 214
Pseudomonas aeruginosa 36 45 36 38 136
Enterococcus faecalis 32 32 32 37 147
Staphylococcus epidermidis 22 47 22 29 143
Group B Streptococcus 22 19 22 25 68
Enterobacter cloacae 20 22 20 18 80
Group A Streptococcus 19 17 19 27 78
Proteus mirabilis 16 18 16 14 55
Candida albicans 15 14 15 18 60
Serratia marcescens 15 9 15 9 37
Streptococcus mitis 14 12 14 13 43
Group G Streptococcus 14 14 14 16 50
Acinetobacter calcoaceticus 
–baumanii complex 12 5 12 11 36
Klebsiella oxytoca 12 21 12 17 71
Streptococcus bovis 12 6 12 5 22
Enterococcus faecium 9 8 9 9 51
Subtotal 989 950 989 930 3826
Other isolate types 223 260 223 229 972
Total 1212 1210 1212 1159 4798
Table 19: Trends in resistance patterns to key antimicrobials in S. aureus,
S. pneumoniae and enterococci, Victoria, January–March 2004
Period Staphylococcus Streptococcus Enterococcus Enterococcus
aureus pneumoniae faecalis faecium
Methicillin Isolates Penicillin Isolates Vancomycin Isolates Vancomycin Isolates
resistant tested non- tested resistant tested resistant tested
susceptible
(%) (n) (%) (n) (%) (n) (%) (n)
Jan–Mar 29% 257 5% 63 3% 32 22% 9
2004
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Table 20. Notifications of infectious diseases, by Department of Human Services Region, 1 January to 31 March 2004 and hi
Barwon South Grampians Loddon Mallee Hume Gippsland
Western
Notifiable Disease 2004 ytd 2003 ytd 2004 ytd 2003 ytd 2004 ytd 2003 ytd 2004 ytd 2003 ytd 2004 ytd 2003 ytd
Blood Borne Diseases
Hepatitis B - Acute 0 4 0 1 0 1 0 0 2 4
Hepatitis B - Chronic/Unknown 4 24 3 1 2 4 1 5 1 5
Hepatitis C - Newly acquired 4 3 1 0 2 3 1 2 2 2
Hepatitis C - Not further specified 38 59 25 31 30 33 43 40 35 37
Hepatitis D 0 0 0 0 0 0 0 0 0 0
Enteric Diseases
Campylobacter infection 157 165 52 50 68 84 102 78 126 100
Cholera 0 0 0 0 0 0 0 0 0 0
Cryptosporidiosis 0 1 7 0 2 1 12 8 13 17
Food/Water/Environmental - Other 0 3 1 5 2 7 0 5 1 6
Giardiasis 16 21 4 9 12 15 4 9 10 11
Haemolytic Uraemic Syndrome 0 0 0 0 0 1 1 0 0 0
Hepatitis A 2 1 0 0 0 2 0 2 0 1
Hepatitis E 0 0 1 0 0 0 0 0 0 0
Listeriosis 0 0 0 0 0 0 0 1 0 1
Paratyphoid 0 0 0 0 0 0 0 0 0 0
Salmonellosis 26 24 18 12 16 28 20 28 18 24
Shigellosis 0 0 1 0 0 0 1 0 0 0
Typhoid 0 0 0 0 0 0 0 0 0 1
Vero Toxin producing E.coli 2 0 1 0 0 1 0 0 0 0
Other Infectious Notifiable Diseases
Invasive Meningococcal Disease – Group B 1 1 1 0 0 1 0 0 1 1
Invasive Meningococcal Disease – Group C 1 2 0 0 0 0 0 1 1 0
Invasive Meningococcal Disease – Other 3 1 0 0 0 0 1 0 0 0
Legionella – Other 1 0 0 1 1 1 0 0 1 2
Legionella pneumophila 1 1 0 0 0 0 0 0 0 0 0
Leprosy 0 0 0 0 0 0 0 0 0 0
Mycobacterium infection (non-TB) 1 0 0 0 0 1 0 0 0 2
Mycobacterium tuberculosis 0 1 0 2 0 2 1 0 0 2
Mycobacterium ulcerans 0 0 0 0 0 0 0 0 0 4
Syndromes 0 0 0 0 0 0 0 0 0 0
Sexually Transmitted Infections
Chlamydia 131 105 76 45 91 56 60 47 66 42
Gonococcal Infection 7 2 4 1 6 2 4 4 0 3
Syphilis - infectious 0 0 0 0 0 0 0 1 0 0
Syphilis - other 3 2 0 2 2 1 2 2 0 1
Vaccine Preventable Diseases
Haemophilus influenzae type b 0 0 0 0 0 0 0 0 0 0
Influenza 0 0 0 0 0 0 0 0 1 1
Invasive Pneumococcal Disease 10 10 4 6 2 3 5 2 4 5
Measles 1 0 0 0 0 10 0 3 0 0
Mumps 0 0 0 0 0 0 0 0 0 0
Pertussis 25 9 3 12 26 5 21 14 13 25
Rubella 0 0 0 0 0 0 0 0 0 0
Tetanus 0 0 0 0 0 0 0 0 0 0
Vector Borne Diseases
Arbovirus - Alphavirus 1 0 4 0 15 3 6 0 6 3
Arbovirus - Flavivirus 0 0 0 1 0 0 1 0 0 0
Malaria 0 0 0 0 1 1 0 1 1 0
Zoonoses
Brucellosis 0 0 0 0 0 0 0 0 0 0
Leptospirosis 0 2 0 0 0 0 0 0 0 1
Psittacosis 0 0 10 2 3 0 5 1 0 0
Q Fever 0 2 0 3 1 0 1 3 1 3
Est. 2002 resident population 343,999 209,243 296,067 253,250 240,948
Notes
1. The data are preliminary figures only and may be subject to revision
2. ABS estimated resident population data, June 2001—Victorian total includes 99 unincorporated (French Island).
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istorical comparisons*
Western Northern Eastern Southern Unknown Victoria
Metropolitan Metropolitan Metropolitan Metropolitan
2004 ytd 2003 ytd 2004 ytd 2003 ytd 2004 ytd 2003 ytd 2004 ytd 2003 ytd 2004 ytd 2003 ytd 2004 ytd 2003 ytd 2003 total
6 9 3 6 5 6 7 11 1 1 24 43 157
92 105 72 69 88 80 86 106 41 37 390 436 1613
0 5 4 6 3 4 0 5 2 5 19 35 115
124 182 134 149 85 128 201 226 48 58 763 943 3702
0 1 0 1 0 0 0 0 0 0 0 2 13
184 205 241 237 409 285 402 311 58 48 1799 1563 5644
0 0 0 0 1 0 0 0 0 0 1 0 0
6 4 6 6 5 11 9 11 2 1 62 60 214
19 119 6 50 9 72 15 41 136 95 189 403 847
32 28 28 24 35 37 58 62 5 7 204 223 772
0 0 0 0 0 1 0 0 0 0 1 2 4
2 2 5 5 1 7 6 8 1 0 17 28 92
1 0 1 0 2 0 0 0 0 0 5 0 2
0 0 0 1 0 5 3 0 0 0 3 8 21
1 2 2 0 1 1 1 2 0 0 5 5 10
32 148 49 59 81 93 76 99 13 19 349 534 1264
3 3 4 4 2 6 3 1 1 1 15 15 50
2 3 1 0 1 6 1 2 0 0 5 12 19
0 0 0 0 0 0 0 1 0 0 3 2 3
1 1 1 1 0 0 4 2 1 0 10 7 55
0 2 0 3 1 1 1 4 0 0 4 13 47
0 1 2 2 0 3 1 1 0 0 7 8 27
3 5 3 5 3 1 4 0 0 0 16 15 57
1 0 0 8 4 2 2 4 0 0 8 14 33
0 0 0 1 0 0 0 0 0 0 0 1 2
0 2 2 0 2 1 0 3 0 0 5 9 33
28 17 14 12 22 10 16 25 0 0 81 71 329
0 0 0 0 1 0 0 2 0 0 1 6 11
0 0 0 0 0 0 0 0 0 0 0 0 3
273 240 326 254 297 234 515 368 159 136 1994 1527 6484
51 41 60 60 31 33 79 85 74 64 316 295 1166
4 0 3 1 0 4 6 3 6 1 19 10 55
16 14 6 11 9 9 17 23 11 17 66 82 302
0 0 0 0 0 0 0 0 0 0 0 0 1
2 0 2 0 4 0 7 0 2 1 18 2 658
6 3 8 10 12 17 16 13 4 0 71 69 441
0 0 0 0 0 0 3 0 0 0 4 13 38
1 0 0 0 1 0 0 0 0 0 2 0 4
27 10 25 19 34 22 42 17 21 1 237 134 610
0 0 0 0 0 2 0 1 0 0 0 3 3
0 0 0 0 0 0 0 0 0 0 0 0 1
3 0 6 0 6 1 4 1 0 0 51 8 23
0 0 0 1 3 1 0 4 0 0 4 7 18
4 4 1 1 3 9 1 5 3 1 14 22 60
0 0 0 0 0 0 0 0 0 0 0 0 4
0 0 0 0 0 0 0 0 1 0 1 3 10
7 4 7 5 10 3 7 3 1 0 50 18 103
0 0 0 0 0 0 0 0 0 0 3 11 18
630,838 772,295 973,307 1,137,188 4,857,228
The Victorian Infectious Diseases Bulletin is published quarterly and provides
summaries of infectious diseases surveillance data, local news, outbreak
investigations, infection control procedures, clinical cases of general interest and
brief reports on original clinical or laboratory based research. The bulletin is
distributed free of charge to persons with an interest in the control and treatment of
infectious diseases in Victoria.
Contributions are invited on any topic dealing with the control of infectious
diseases. These may be in the form of articles, short reports or letters. Submissions
should be in Microsoft Word IBM-compatible format with Vancouver-style
references. We encourage submissions in electronic format. Original data from
which graphs and figures have been prepared should be included. Submissions will
be edited to conform with the style of the bulletin. 
The editors recognise and thank the individuals and organisations who contribute to
the surveillance and management of infectious diseases. We remind authors of their
responsibility to cite appropriate persons as authors and to acknowledge separately
those whose work contributed significantly but did not justify authorship.
Any material included in the Victorian Infectious Diseases Bulletin may be
reproduced in whole or part if appropriately acknowledged. Opinions expressed in
the bulletin are those of the authors and not necessarily those of the Department of
Human Services. Data are subject to revision.
This publication can be found online at: http://www.dhs.vic.gov.au/phd/vidb/
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